Stay updated on A4250 in Children With PFIC Types 1 or 2 Clinical Trial.

Sign up to get notified when there's something new on the A4250 in Children With PFIC Types 1 or 2 Clinical Trial. page.
Latest website image capture
Clouds background image

Latest updates to the A4250 in Children With PFIC Types 1 or 2 Clinical Trial. page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:26:05.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has been updated to AlbireoPharma ( ) 8 on the webpage, indicating a change in the study details related to the efficacy and safety investigation of A4250 in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.
    Difference
    0.3%
    Check dated 2024-06-06T14:51:46.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that they must have a clinical diagnosis of PFIC Type 1 or 2, a body weight above 5 kg, and clinical genetic confirmation, among other criteria.
    Difference
    23%
    Check dated 2024-05-22T21:33:22.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:45.000Z thumbnail image

Stay in the know with updates to A4250 in Children With PFIC Types 1 or 2 Clinical Trial.

Enter your email address, and we'll notify you when there's something new on the A4250 in Children With PFIC Types 1 or 2 Clinical Trial. page.